Edition:
United States

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

4.80USD
2:10pm EDT
Change (% chg)

$-0.03 (-0.62%)
Prev Close
$4.83
Open
$4.85
Day's High
$4.86
Day's Low
$4.80
Volume
2,345
Avg. Vol
21,098
52-wk High
$7.73
52-wk Low
$4.42

Latest Key Developments (Source: Significant Developments)

Therapix Biosciences Expects To Test THX-110 In Early Study In Q2
Wednesday, 7 Feb 2018 08:30am EST 

Feb 7 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018.THERAPIX BIOSCIENCES - COMPLETES PRE-IND COMMUNICATION WITH FDA ON THX-110 FOR TOURETTE SYNDROME: CLINICAL DEVELOPMENT TO PROCEED AS PROJECTED.  Full Article

Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary
Tuesday, 9 Jan 2018 08:37am EST 

Jan 9 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018.THERAPIX BIOSCIENCES LTD - ‍EXPANDING INTO PRECISION MEDICINE THROUGH A NEW FULLY-OWNED SUBSIDIARY IN ORDER TO DEVELOP "NOVEL SOLUTIONS FOR PAIN"​.  Full Article

Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement
Tuesday, 26 Dec 2017 04:10pm EST 

Dec 26 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING.THERAPIX BIOSCIENCES SAYS IS IN THE PROCESS OF SEARCHING FOR A NEW CHIEF FINANCIAL OFFICER.  Full Article

Therapix Biosciences Q3 loss per share $0.30
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Therapix Biosciences Ltd : :Therapix Biosciences reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.30.Therapix Biosciences Ltd - ‍cash totaled $10.7 Million as of September 30, 2017, compared to $11.8 million as of June 30, 2017​.  Full Article

Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea
Wednesday, 18 Oct 2017 08:30am EDT 

Oct 18 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea.  Full Article

THERAPIX SIGNS FORMULATION DEVELOPMENT, CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01
Friday, 6 Oct 2017 08:30am EDT 

Oct 6 (Reuters) - Therapix Biosciences Ltd :THERAPIX SIGNS FORMULATION DEVELOPMENT AND CLINICAL MANUFACTURING AGREEMENT WITH CATALENT FOR THX-TS01.THERAPIX BIOSCIENCES - ‍ENTERED EXCLUSIVE AGREEMENT WITH CATALENT PHARMA SOLUTIONS FOR FORMULATION, DEVELOPMENT AND CLINICAL MANUFACTURING OF THX-TS01​.THERAPIX BIOSCIENCES - ‍CATALENT TO DEVELOP THX-TS01 IN SOFTGEL FORM IN SUPPORT OF CO'S CLINICAL DEVELOPMENT PROGRAM.  Full Article

Therapix Biosciences posts Q2 loss per share $0.54
Thursday, 10 Aug 2017 08:00am EDT 

Aug 10 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.54.  Full Article

Therapix Biosciences and Hannover Medical School enter into clinical trial agreement
Monday, 8 May 2017 08:30am EDT 

May 8 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and the Hannover Medical School enter into an investigator-initiated clinical trial agreement to assess the effect of txh-ts01 in patients with tourette syndrome.Therapix Biosciences - entered into trial agreement with hannover medical school to conduct proof-of-concept phase ii clinical study with lead compound, thx-ts01.Therapix Biosciences - trial agreement to conduct proof-of-concept phase ii clinical study with thx-ts01, for patients suffering from tourette syndrome.  Full Article

Therapix Biosciences names Josh Blacher CFO
Wednesday, 3 May 2017 08:30am EDT 

May 3 (Reuters) - Therapix Biosciences Ltd ::Therapix Biosciences announces the appointment of Josh Blacher as chief financial officer.Prior to joining Therapix, Blacher served as Chief Financial Officer at Galmed Pharmaceuticals.  Full Article

Therapix signs exclusive license agreement with Yissum
Wednesday, 5 Apr 2017 08:55am EDT 

Therapix Biosciences Ltd : Therapix signs exclusive license agreement with Yissum for nasal drug delivery technology .Therapix Biosciences - under terms of deal, Yissum to give co exclusive, sub-licensable, royalty-bearing license for nasal delivery of cannabinoids technology.  Full Article

BRIEF-Therapix Biosciences - Co Terminated Research & License Agreement Between Co, Yissum Research Development Co

* THERAPIX BIOSCIENCES - ON MARCH 18, 2018 CO TERMINATED RESEARCH & LICENSE AGREEMENT BETWEEN CO, YISSUM RESEARCH DEVELOPMENT CO, DATED MARCH 30, 2017 Source text: (https://bit.ly/2F372wh) Further company coverage: (Reuters.Briefs@thomsonreuters.com)